Regenerative medicine: Cell conversion factors predicted

Identifying cell types

Skin cells and neurons are not the same, that much is clear just from looking at them. But even cells of the same type can have fine differences in genetic activity that sometimes have a powerful influence on their cellular function, giving rise to different cell subpopulations or subtypes. For example, dopaminergic neurons are nerve cells in the brain that produce the neurotransmitter dopamine. In the course of Parkinson's disease, these cells in the substantia nigra of the midbrain die off -- but not all of them. Only one specific subtype of these cells dies off. "The identity of a particular cell subtype is characterised and maintained by a few interacting regulatory genes," del Sol explains. "Yet the differences between the subtypes are subtle and difficult to detect using the existing analytical methods."

In order to address this problem, del Sol and his team developed the computational platform "TransSyn." Its predictions are based on the gene expression programs of individual cells in a population. Following a multistep computational pipeline, TransSyn searches for subtle differences between cell subtypes. The researchers know there are always multiple, synergistically interacting regulatory genes working together to characterise a subtype. Once these synergistic 'transcriptional cores' have been identified for each subtype, there are enough data to move onto laboratory applications, such as converting one cell subtype into another. To do that, the scientists treat cell cultures with specific factors to alter their gene expression profiles. These factors activate certain genes while deactivating others.

Cooperation with the Karolinska Institute

Working from the predictions made in Luxembourg, the researchers at the Swedish Karolinska Institute, converted human neuroepithelial stem cells (hNES cells) from the hindbrain into midbrain dopaminergic neuron progenitors capable of developing into dopaminergic neurons. "This could prove to be a strategy for cell therapy in Parkinson's disease," del Sol asserts.

Testing the predictions in the lab

The Luxembourg researchers are continuing to test the applicability of their platform at present, for example in collaboration with the Gladstone Institute in the USA. The American researchers, led by Deepak Srivastava, are looking for an efficient way to convert heart cells of the right ventricle into those of the left ventricle and vice versa -- because the two subtypes exhibit subtle differences in their gene expression profiles and thus functional activity. "We have the predictions already. Our colleagues in the US will be starting their experiments in the next few weeks," del Sol said.